KalVista Pharmaceuticals (NASDAQ:KALV) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04, Yahoo Finance reports.

KalVista Pharmaceuticals Trading Down 4.1 %

Shares of NASDAQ:KALV opened at $12.34 on Friday. The firm has a 50 day simple moving average of $13.17 and a 200-day simple moving average of $12.42. KalVista Pharmaceuticals has a twelve month low of $7.21 and a twelve month high of $16.88. The company has a market capitalization of $520.60 million, a PE ratio of -3.63 and a beta of 0.91.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,135 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the sale, the insider now directly owns 83,745 shares of the company’s stock, valued at $1,038,438. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, insider Christopher Yea sold 7,102 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $85,295.02. Following the transaction, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 2,135 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the completion of the sale, the insider now owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. The disclosure for this sale can be found here. Insiders have sold 23,452 shares of company stock valued at $282,491 in the last ninety days. Insiders own 12.30% of the company’s stock.

Wall Street Analyst Weigh In

KALV has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday. Finally, Cantor Fitzgerald raised KalVista Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 26th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.